AIPAC 003
Presented by Dr Frederic Forget (Centre Hospitalier de l’Ardennes, Libramont, Belgium)
Dr Frederic Forget discusses in this poster AIPAC-003, a new study with eftilagimod Alpha (efti).
The poster discusses AIPAC, a new compound acting as a LAG-3 agonist that aims to convert cold tumours into hot tumours. In a breast cancer trial, the dose was increased to improve response rates.
In an earlier trial, efti combined with paclitaxel improved OS by three months compared to paclitaxel alone, though not statistically significant. This trial aims to show that the increased dose significantly impacts survival outcomes.
References:
Forget F. et al., ASCO 2024 – abstract 1125
